Health economics of allergen-specific immunotherapy in the United States

Journal of Allergy and Clinical Immunology

Volumn 127, Issue 1, 2011, Pages 39-43

  Lockey, Richard F ^a   Hankin, Cheryl S ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b BioMedEcon LLC   (United States)

Author keywords

allergen immunotherapy; cost benefit analysis

Indexed keywords

ALLERGEN; ANTIALLERGIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; DECONGESTIVE AGENT; HOUSE DUST ALLERGEN; IMMUNOMODULATING AGENT;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIBIOTIC THERAPY; BILLING AND CLAIMS; CLINICAL EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FOLLOW UP; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH MAINTENANCE ORGANIZATION; HOSPITAL CARE; HOSPITAL PATIENT; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; MEDICAID; NOSE POLYP; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SINUSITIS; SUBLINGUAL IMMUNOTHERAPY; UNITED STATES;

EID: 78650912370     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.09.033     Document Type: Editorial

References (21)

1. R. Ariano, P. Berto, D. Tracci, C. Incorvaia, and F. Frati Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma Allergy Asthma Proc 27 2006 159 163
2. R. Ariano, P. Berto, C. Incorvaia, G. Di Cara, R. Boccardo, and S. La Grutta Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma Ann Allergy Asthma Immunol 103 2009 254 259
3. J. Pokladnikova, I. Krcmova, and J. Vlcek Economic evaluation of sublingual vs subcutaneous allergen immunotherapy Ann Allergy Asthma Immunol 100 2008 482 489
4. K.D. Petersen, D. Gyrd-Hansen, and R. Dahl Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy Allergol Immunopathol (Madr) 33 2005 296 302 (Pubitemid 47250520)
5. J.G. Donahue, D.K. Greineder, L. Connor-Lacke, C.F. Canning, and R. Platt Utilization and cost of immunotherapy for allergic asthma and rhinitis Ann Allergy Asthma Immunol 82 1999 339 347
6. P. Berto, M. Bassi, C. Incorvaia, F. Frati, P. Puccinelli, and C. Giaquinto Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma Allerg Immunol (Paris) 37 2005 303 308
7. C. Le Pen, C. Rumeau-Pichen, and H. Lillin L'impact de l'immunothérapie specifique sur le couts directs de la maladie allergique: une etude pragmatique Rev Franc Allergol Immunol Clin 37 1997 11 14
8. C.S. Hankin, L. Cox, D. Lang, A. Levin, G. Gross, and G. Eavy Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs J Allergy Clin Immunol 121 2008 227 232
9. C.S. Hankin, L. Cox, D. Lang, A. Bronstone, P. Fass, and B. Leatherman Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study Ann Allergy Asthma Immunol 104 2010 79 85
10. P. Berto, F. Frati, C. Incorvaia, G. Cadario, R. Contiguglia, and M. Di Gioacchino Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study Curr Med Res Opin 24 2008 261 266
11. C. Bachert, U. Vestenbaek, J. Christensen, U.K. Griffiths, and P.B. Poulsen Cost-effectiveness of grass allergen tablet (GRAZAX(R)) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective Clin Exp Allergy 37 2007 772 779
12. J.A. Bernstein Pharmacoeconomic considerations for allergen immunotherapy Clin Allergy Immunol 18 2004 151 164
13. B. Brüggenjürgen, T. Reinhold, R. Brehler, E. Laake, G. Wiese, and U. Machate Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma Ann Allergy Asthma Immunol 101 2008 316 324
14. H. Keiding, and K.P. Jorgensen A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries Curr Med Res Opin 23 2007 1113 1120
15. S. Nasser, U. Vestenbaek, A. Beriot-Mathiot, and P.B. Poulsen Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma Allergy 63 2008 1624 1629
16. L.F. Omnes, J. Bousquet, P. Scheinmann, F. Neukirch, G. Jasso-Mosqueda, and A. Chicoye Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France Allerg Immunol (Paris) 39 2007 148 156
17. P.K. Schadlich, and J.G. Brecht Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany Pharmacoeconomics 17 2000 37 52
18. K. Buchner, and M. Siepe Nutzen der Hyposensibilierung unter wirtschaftlichen Aspekten Allergo J 4 1995 156 163
19. G.W. Canonica, P.B. Poulsen, and U. Vestenbaek Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe Respir Med 101 2007 1885 1894
20. T.J. Sullivan, J.C. Selner, R. Patterson, J. Portnoy, and M. Seligman Expert care and immunotherapy for asthma: a review of published studies with emphasis on patient outcome and cost. ACAAI Monograph 1996 Arlington Heights (IL): American College of Allergy, Asthma and Immunology p. 1-25
21. A.W. Law, S.D. Reed, J.S. Sundy, and K.A. Schulman Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey J Allergy Clin Immunol 111 2003 296 300